Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Atroflam
- Development stage
- Unknown
- Lead developer
- Atro Pharma
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
**Atroflam** is a marketed topical fixed-dose analgesic gel from Atro Pharma for local musculoskeletal pain relief. The gel contains diclofenac 1% w/w, capsaicin 0.025% w/w, methyl salicylate 10% w/w, menthol 5% w/w, and linseed oil 3% w/w. Its intended effects combine local anti-inflammatory activity from diclofenac with counterirritant and sensory analgesic effects from capsaicin, methyl salicylate, and menthol, helping relieve pain, swelling, and discomfort affecting muscles and joints.
- Brand names
- AtroflamAtroflam Gel
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on Atroflam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Atroflam.